

BRUKINSA demonstrated superiority in progression-free survival over chemoimmunotherapy as a first-line treatment for patients with chronic lymphocytic leukemia Consistent efficacy was observed...


Oral presentation at ASH 2021 features positive phase 2 data in Japanese patients with relapsed/refractory ATL Orphan Drug Designation granted with regulatory...


Follow-up results from Phase 2 trial suggested intolerable adverse events leading to discontinuation of previous BTK inhibitor therapy were unlikely to recur...


LITTLETON, Colo.–(BUSINESS WIRE)–Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) is pleased to report that its previously announced rights offering...
DAYTONA BEACH, Fla., Dec. 10, 2021 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced the...


Pony.ai now has autonomous driving public road testing permits in all four Tier-1 cities in China, making it one of the first...


DUBLIN–(BUSINESS WIRE)–The “Semiconductor Intellectual Property Global Market Report 2021: COVID-19 Growth and Change” report has been added to ResearchAndMarkets.com’s offering. The global...


DUBLIN–(BUSINESS WIRE)–The “Semiconductor Intellectual Property Global Market Report 2021: COVID-19 Growth and Change” report has been added to ResearchAndMarkets.com’s offering. The global...


DUBLIN–(BUSINESS WIRE)–The “Global & Asia Pacific High Throughput Screening Market Outlook 2030” report has been added to ResearchAndMarkets.com’s offering. The market is...
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting,...